| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 09/06/2023 | 797.44% | HC Wainwright & Co. | → $28 | Reiterates | Buy → Buy |
| 08/22/2023 | 220.51% | Cantor Fitzgerald | → $10 | Reiterates | Overweight → Overweight |
| 08/15/2023 | 220.51% | Cantor Fitzgerald | $14 → $10 | Maintains | Overweight |
| 08/10/2023 | 444.87% | Oppenheimer | $18 → $17 | Maintains | Outperform |
| 08/10/2023 | 797.44% | HC Wainwright & Co. | → $28 | Reiterates | Buy → Buy |
| 07/24/2023 | 348.72% | Cantor Fitzgerald | → $14 | Reiterates | Overweight → Overweight |
| 06/22/2023 | 797.44% | HC Wainwright & Co. | → $28 | Reiterates | Buy → Buy |
| 05/04/2023 | 797.44% | HC Wainwright & Co. | → $28 | Reiterates | → Buy |
| 03/06/2023 | 797.44% | HC Wainwright & Co. | → $28 | Reiterates | → Buy |
| 12/08/2022 | 124.36% | Jefferies | $17 → $7 | Downgrades | Buy → Hold |
| 11/15/2022 | 124.36% | Jefferies | → $7 | Downgrades | Buy → Hold |
| 07/20/2022 | 541.03% | Oppenheimer | → $20 | Initiates Coverage On | → Outperform |
| 11/04/2021 | 797.44% | HC Wainwright & Co. | $27 → $28 | Maintains | Buy |
| 07/21/2021 | 765.38% | HC Wainwright & Co. | $34 → $27 | Maintains | Buy |
| 03/11/2021 | 669.23% | Stifel | $4 → $24 | Upgrades | Hold → Buy |
| 12/03/2020 | 925.64% | Cantor Fitzgerald | → $32 | Initiates Coverage On | → Overweight |
| 11/23/2020 | 989.74% | HC Wainwright & Co. | $33 → $34 | Maintains | Buy |
| 08/26/2020 | 733.33% | Piper Sandler | → $26 | Initiates Coverage On | → Overweight |
| 08/04/2020 | 957.69% | HC Wainwright & Co. | → $33 | Initiates Coverage On | → Buy |
| 04/16/2020 | 284.62% | Jefferies | → $12 | Initiates Coverage On | → Buy |
What is the target price for Lumos Pharma (LUMO)?
The latest price target for Lumos Pharma (NASDAQ: LUMO) was reported by HC Wainwright & Co. on September 6, 2023. The analyst firm set a price target for $28.00 expecting LUMO to rise to within 12 months (a possible 797.44% upside). 11 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Lumos Pharma (LUMO)?
The latest analyst rating for Lumos Pharma (NASDAQ: LUMO) was provided by HC Wainwright & Co., and Lumos Pharma reiterated their buy rating.
When is the next analyst rating going to be posted or updated for Lumos Pharma (LUMO)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Lumos Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Lumos Pharma was filed on September 6, 2023 so you should expect the next rating to be made available sometime around September 6, 2024.
Is the Analyst Rating Lumos Pharma (LUMO) correct?
While ratings are subjective and will change, the latest Lumos Pharma (LUMO) rating was a reiterated with a price target of $0.00 to $28.00. The current price Lumos Pharma (LUMO) is trading at is $3.12, which is within the analyst's predicted range.